Bioequivalence Study of Vigabatrin ORPHELIA Pharma 500mg Soluble Tablets and SabrilTM 500mg Granules for Oral Administration

Methodology:

The study was an open label, randomized, crossover, 2 periods study in 20 healthy male/female volunteers. Subjects received 500 mg of the new formulation of soluble tablets vigabatrin or Sabril, as single oral administration in 2 different study periods depending on the randomization, with a 7-days wash out period between administrations

Study Overview

• Status: Completed
• Conditions: Therapeutic Equivalency
• Intervention / Treatment: Drug: VGB-ST

Detailed Description

Objectives:

Primary objective:

Evaluate bioequivalence between a new paediatric formulation of vigabatrin (VGB-ST) and Sabril granules for oral administration.

Secondary objective:

• Define pharmacokinetic parameters of the new paediatric formulation soluble tablets of vigabatrin (VGB-ST)
• Assess the safety of the new formulation of soluble tablets VGB-ST versus Sabril

• Study Type: Interventional
• Enrollment (Actual): 20
• Phase: Phase 1

Contacts and Locations

Study Locations

• France
  • Gières, France, 38610
    • Eurofins Optimed

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 46 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Healthy male and female subject, aged between 18 and 50 years inclusive;
2. Females of childbearing potential/Sexually active males with partner of childbearing potential: commitment to consistently and correctly use an acceptable method of birth control (oral, transdermal, systemic or implant contraception birth control, intrauterine devices, diaphragm, condoms or abstinence) for the duration of the trial and for 1 month after the last study drug administration; Females of non-childbearing potential: either surgically sterilized or at least 1 year postmenopausal (amenorrhoea duration at least 12 months);
3. Non breast-feeding female and negative pregnancy test at screening baseline;
4. Non-smoker subject or smoker of not more than 5 cigarettes per day;
5. Body Mass Index (BMI) between 18,5 and 25 kg/m2 inclusive;
6. Considered as healthy after a comprehensive clinical assessment (detailed medical history and complete physical examination);
7. Normal Blood Pressure (BP) and Heart Rate (HR) at the screening visit after 10 minutes in supine position
8. Normal ECG recording on a 12-lead ECG at the screening visit
9. Laboratory parameters within the normal range of the laboratory (hematological, blood chemistry tests, urinalysis). Individual values out of the normal range could be accepted if judged clinically non relevant by the Investigator;
10. Normal dietary habits;
11. Signing a written informed consent prior to selection;
12. Covered by Health Insurance System and / or in compliance with the recommendations of National Law in force relating to biomedical research.

Exclusion Criteria:

1. Any history or presence of cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, haematological, neurologic, psychiatric, systemic, infectious disease or psychiatric disorders;
2. Frequent headaches and / or migraine, recurrent nausea and / or vomiting;
3. History of abnormal vision (e.g. reduced visual field, retinopathy, etc…);
4. Abnormal visual field recorded during the inclusion period;
5. Evidence of any clinically significant acute or chronic disease;
6. Symptomatic hypotension whatever the decrease of blood pressure or asymptomatic postural hypotension defined by a decrease in SBP or DBP equal to or greater than 20 mmHg within two minutes when changing from the supine to the standing position;
7. Surgery or blood donation (including in the frame of a clinical trial) within 2 months before administration;
8. General anaesthesia within 3 months before administration;
9. Presence or history of drug hypersensitivity, asthma or allergic disease diagnosed and treated by a physician;
10. Inability to abstain from intensive muscular effort;
11. No possibility of contact in case of emergency;
12. Any drug intake (except paracetamol or contraception) during the last month prior to the first administration;
13. History or presence of drug or alcohol abuse (alcohol consumption > 40 grams / day);
14. Excessive consumption of beverages containing xanthine bases (> 4 cups or glasses / day);
15. Positive Hepatitis B surface (HBs) antigen or anti Hepatitis C Virus (HCV) antibody (not including HSV), or positive results for Human Immunodeficiency Virus (HIV) 1 or 2 tests;
16. Positive results of screening for drugs of abuse;
17. Subject who, in the judgment of the Investigator, was likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development;
18. Exclusion period of a previous study;
19. Administrative or legal supervision;
20. Subject who would receive more than 4500 euros as indemnities for his participation in biomedical research within the 12 last months, including the indemnities for the present study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: VGB-ST; Name of the compound: Vigabatrin ORPHELIA Pharma (VGB-ST) Pharmaceutical form: Soluble tablet Dose per administration: 500 mg Timing for administration: Single oral administration on P1D1 or P2D1 according to randomization. Batch N°: 16.92.042 (expiry date: 31.05.2017)	Drug: VGB-ST; Single oral administration of 500 mg VGB-ST; Other Names: vigabatrin soluble tablets; Kigabeq
Active Comparator: Sabril; Name of the compound: Sabril (vigabatrin) Pharmaceutical form: granules (sachet) Dose per administration: 500 mg Timing for administration: Single oral administration on P1D1 or P2D1 according to randomization. Batch N°: 6810 (expiry date: 31.05.2019)	Drug: VGB-ST; Single oral administration of 500 mg VGB-ST; Other Names: vigabatrin soluble tablets; Kigabeq

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary pharmacokinetic parameters (Bioequivalence)	The following pharmacokinetic parameters were determined from S(+) enantiomer of vigabatrin plasma concentrations: Cmax	day 1 or 2
Primary pharmacokinetic parameters (Bioequivalence)	The following pharmacokinetic parameters were determined from S(+) enantiomer of vigabatrin plasma concentrations: AUC0-t	day 1 or 2

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Secondary pharmacokinetic parameters	The following pharmacokinetic parameters were determined from S(+) enantiomer of vigabatrin plasma concentrations: AUC0-inf	day 1 or 2
Secondary pharmacokinetic parameters	The following pharmacokinetic parameters were determined from S(+) enantiomer of vigabatrin plasma concentrations: tmax	day 1 or 2
Secondary pharmacokinetic parameters	The following pharmacokinetic parameters were determined from S(+) enantiomer of vigabatrin plasma concentrations: λ	day 1 or 2
Secondary pharmacokinetic parameters	The following pharmacokinetic parameters were determined from S(+) enantiomer of vigabatrin plasma concentrations: t1/2	day 1 or 2
Secondary pharmacokinetic parameters	The following pharmacokinetic parameters were determined from S(+) enantiomer of vigabatrin plasma concentrations: residual area	day 1 or 2

Collaborators and Investigators

• Sponsor: Orphelia Pharma
• Investigators: Study Director: PharmD PharmD, PhD, Orphelia Pharma

Study record dates

Study Major Dates

• Study Start (Actual): April 4, 2017
• Primary Completion (Actual): August 8, 2017
• Study Completion (Actual): August 8, 2017

Study Registration Dates

• First Submitted: March 27, 2020
• First Submitted That Met QC Criteria: July 8, 2020
• First Posted (Actual): July 13, 2020

Study Record Updates

• Last Update Posted (Actual): July 13, 2020
• Last Update Submitted That Met QC Criteria: July 8, 2020
• Last Verified: July 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; GABA Agents; Anticonvulsants; Vigabatrin
• Other Study ID Numbers: ORP-VGB-I-a; 2017-000038-67 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No